CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use. a R t I C l E S npg
CRISPR-Cas (clustered, regularly interspaced, short palindromic repeats (CRISPR)-CRISPR-associated (Cas)) RGNs are robust genome-editing reagents with a broad range of research and potential clinical applications 1, 2 . However, therapeutic use of RGNs in humans will require a comprehensive knowledge of their off-target effects to minimize the risk of deleterious outcomes. DNA cleavage by Streptococcus pyogenes Cas9 nuclease is directed by a programmable, ~100-nt guide RNA (gRNA) 3 . Targeting can be mediated by 17-20 nt at the gRNA 5ʹ-end, which are complementary to the complementary strand of a 'protospacer' DNA site that lies next to a protospacer adjacent motif (PAM) of the form 5ʹ-NGG. Repair of blunt-ended, Cas9induced, DNA double-stranded breaks (DSBs) within the protospacer by nonhomologous end-joining (NHEJ) can induce variable-length insertion/deletion mutations (indels). Our group and others have previously shown that unintended RGN-induced indels can occur at off-target cleavage sites that differ by as many as five positions within the protospacer or that harbor alternative PAM sequences [4] [5] [6] [7] . In addition, chromosomal translocations can result from joining of on-and off-target, RGN-induced cleavage events [8] [9] [10] [11] . For clinical applications, identification of even low-frequency alterations will be critically important because ex vivo and in vivo therapeutic strategies using RGNs are expected to require the modification of very large cell populations. The induction of oncogenic transformation in even a rare subset of cell clones (e.g., inactivating mutations of a tumor suppressor gene or formation of a tumorigenic chromosomal translocation) is of particular concern because such an alteration could lead to unfavorable clinical outcomes. The identification of indels or higher-order rearrangements that can occur anywhere in the genome is a challenge that is not easily addressed, and sensitive methods for unbiased, genome-wide identification of RGN-induced, off-target DSBs in living cells have not yet been described 12, 13 . Whole genome resequencing has been used to attempt to identify RGN off-target alterations in edited single-cell clones 14, 15 , but the exceedingly high projected cost of sequencing very large numbers of genomes makes this method impractical for finding low-frequency events in cell populations 12 . We and others have used focused deep sequencing to identify indel mutations at potential off-target sites identified either by sequence similarity to the on-target site 4, 5 or by in vitro selection from partially degenerate, binding-site libraries 6 . However, these approaches are biased because they assume that off-target sequences are closely related to the on-target site and, as a result, may miss potential off-target sites elsewhere in the genome. ChIP-seq has also been used to identify off-target binding sites for gRNAs complexed with catalytically dead Cas9 (dCas9), but the majority of published work suggests that very few, if any, of these sites represent off-target sites of cleavage by active Cas9 nuclease [16] [17] [18] [19] .
Here, we describe the development of GUIDE-seq, which enabled us to generate global specificity landscapes for 13 different RGNs in living human cells. These profiles revealed that the total number of off-target DSBs varied widely for individual RGNs and suggested that broad conclusions about the specificity of RGNs from S. pyogenes or other species should be based on characterization of large numbers of gRNAs. Our findings also expanded the range and nature of sequences at which off-target effects can occur and demonstrated that ChIP-seq of dCas9 and two widely used computational approaches do not identify many of the sites found by GUIDE-seq. Our method also identified RGN-independent, DNA breakpoint hotspots that can participate together with RGN-induced DSBs in higher-order genomic alterations such as translocations. Lastly, we show in direct comparisons that truncating the protospacer complementarity region of gRNAs greatly improved their genome-wide, off-target DSB profiles, demonstrating the utility of GUIDE-seq for assessing technology advances designed to improve RGN specificities.
The experiments outlined here provide the most rigorous strategy described to date for evaluating the specificities of RGNs that may be considered for therapeutic use.
RESULTS
Overview of the GUIDE-seq method GUIDE-seq consists of two stages (Fig. 1a) . In stage I, RGN-induced DSBs in the genomes of living human cells are tagged by integration of a blunt, double-stranded oligodeoxynucleotide (dsODN) at these breaks by means of an end-joining process consistent with NHEJ. Start sites of GUIDEseq reads mapped back to the genome enable localization of the DSB to within a few base pairs. Mapped reads for the on-target sites of the ten RGNs we assessed by GUIDE-seq are shown. In all cases, the target site sequence is shown with the 20-bp protospacer sequence to the left and the PAM sequence to the right on the x axis. Note how in all cases the highest peak falls within 3 to 4 bps of the 5ʹ-edge of the NGG PAM sequence, the expected position of an RGN cleavage event. (Equivalent maps for off-target sites are presented in Supplementary Fig. 2 .) (e) Numbers of previously known and novel off-target cleavage sites identified by GUIDE-seq for the ten RGNs analyzed in this study. (f) Scatterplot of ontarget site orthogonality to the human genome (x axis) versus total number of off-target sites detected by GUIDE-seq for the ten RGNs of this report (y axis). Orthogonality was calculated as the total number of sites in the human genome bearing one to six mismatches relative to the on-target site and adjacent to an NGG PAM motif. (g) Scatterplot of on-target site GC content (x axis) versus total number of off-target sites detected by GUIDE-seq for the ten RGNs of this report (y axis). (h) Chromosome ideogram of CRISPR-Cas9 on-and off-target sites for the RGN that targets EMX1. Additional ideograms for the remaining RGNs can be found in Supplementary Figure 3 . (i) Genomic locations of off-target cleavage sites identified by GUIDE-seq for the ten RGNs examined in this study. A R T I C L E S npg RGN components. We then performed a series of PCR reactions initiated by one primer that specifically annealed to the dsODN and another that annealed to the sequencing adapter ( Fig. 1a and Supplementary Fig. 1 ). Because the sequencing adapter was only single tailed, this enabled specific unidirectional amplification of the sequence adjacent to the dsODN, without the bias and background inherent to methods such as linear amplification-mediated (LAM)-PCR 21, 22 . We refer to this strategy as the single-tail adapter/tag (STAT)-PCR method. By performing STAT-PCR reactions using primers that annealed to each of the strands in the dsODN, we obtained reads of adjacent genomic sequence on both sides of each integrated tag ( Fig. 1c) . Incorporation of a random 8-bp molecular barcode during the sequencing adapter ligation process ( Supplementary  Fig. 1 ) allowed for correction of PCR bias introduced during amplification, thereby enabling accurate quantitation of unique sequencing reads obtained from high-throughput sequencing (Supplementary Protocol).
Genome-wide, off-target cleavage profiles of RGNs in cells
We performed GUIDE-seq with Cas9 and ten different gRNAs targeted to various endogenous human genes in either U2OS or HEK293
In stage II, dsODN integration sites in genomic DNA are precisely mapped at the nucleotide level using unbiased amplification and next-generation sequencing. For stage I, we optimized conditions to integrate a blunt, 5ʹ-phosphorylated, 34-bp dsODN into RGN-induced DSBs in human cells. In initial experiments, we did not observe integration of such dsODNs into RGN-induced DSBs (data not shown). Using dsODNs bearing two phosphothiorate linkages at the 5ʹ ends of both DNA strands designed to stabilize the oligos in cells 20 , we observed only modest detectable integration frequencies ( Fig. 1b) . However, addition of phosphothiorate linkages at the 5ʹ and 3ʹ ends of both strands led to robust integration efficiencies ( Fig. 1b) . These rates of integration were only two-to threefold lower than the frequencies of indels induced by RGNs alone at these sites (i.e., in the absence of the dsODN) (data not shown).
For stage II, we developed a strategy that allowed us to selectively amplify and sequence, in an unbiased fashion, only those fragments bearing an integrated dsODN ( Fig. 1a) . We accomplished this by first ligating 'single-tail' , next-generation sequencing adapters to randomly sheared genomic DNA from cells transfected with dsODN and plasmids encoding A R T I C L E S npg varied widely, ranging from zero to >150 ( Fig. 1e) , demonstrating that unwanted genomic cleavage by any particular RGN can be considerable or minimal on the extremes. Control experiments in which we sequenced across dsODN insertions at on-and off-target sites for five of the RGNs revealed that >93% of these sites (123 out of 132) showed detectable evidence of one or more dsODN molecules, consistent with NHEJ-mediated capture into the DSB (data not shown).
human cell lines ( Supplementary Table 1 ). By analyzing the dsODN integration sites (Online Methods), we were able to identify the precise genomic locations of DSBs induced by each of the ten RGNs, mapped to the nucleotide level ( Fig. 1d and Supplementary Fig. 2 ). For the majority of these genomic sites, we identified an overlapping target sequence that was either the on-target site or a closely related off-target site (Online Methods). The total number of off-target sites we identified for each RGN A R T I C L E S npg not see evidence of indels also had low GUIDE-seq read counts, suggesting that the inability to detect mutations at these sites may be related to the sensitivity of sequencing and the sampling depth of our experiments). The range of indel mutation frequencies we detected ranged from 0.03% to 60.1%. Notably, we observed positive linear correlations between GUIDEseq read counts and indel mutation frequencies for off-target sites of all five RGNs (Figs. 3b-f ). Thus, we conclude that GUIDE-seq read counts for a given site provide a quantitative measure of the cleavage efficiency of that sequence by an RGN.
Analysis of RGN-induced, off-target sequence characteristics
Visual inspection of the off-target sites we identified by GUIDEseq for nine RGNs underscored the diversity of variant sequences at
We did not observe a definitive correlation between the total number of off-target sites we detected by GUIDE-seq and orthogonality of the on-target site relative to the human genome ( Fig. 1f) . Similarly, we did not observe a definitive correlation between total number of off-target sites detected by GUIDE-seq and the GC content of the on-target protospacer sequence ( Fig. 1g) . Off-target sequences were found dispersed throughout the genome ( Fig. 1h and Supplementary Fig. 3 ) in exons, introns and noncoding intergenic regions ( Fig.  1i) . Included among the off-target sequences we identified were all 28 of the bona fide off-target sites previously known for four of the RGNs 4,5 (Figs. 1e and 2 and Supplementary Table 2 ). GUIDE-seq also identified a large number of previously unknown off-target sites that map throughout the human genome (Figs. 1e,h,i and 2, Supplementary Table  2 and Supplementary Fig. 3) .
We next tested whether the number of sequencing reads for each offtarget site identified by GUIDE-seq (shown in Fig. 2 and hereafter referred to as "GUIDE-seq read counts") represented a proxy for the relative frequency of indels that would be induced by an RGN alone (i.e., in the absence of a dsODN). We used anchored multiplex PCR (AMP)-based next-generation sequencing (Fig. 3a ) to examine these same sites from cells in which only the nuclease components had been expressed and found that >80% (106 out of 132) harbored variable-length indels characteristic of NHEJ-mediated repair of an RGN cleavage event, further supporting our conclusion that GUIDE-seq identifies bona fide RGN offtarget sites (Supplementary Fig. 4 ). (Many of the sites for which we did , noncanonical PAMs (including previously described NAG which these nucleases can cleave. These sites harbored as many as six mismatches within the protospacer sequence (consistent with a previ- A R T I C L E S npg that determine whether cleavage will occur. In particular, it is worth noting that sites missed included those with as few as one mismatch (Fig. 4c,d) , although the ranking scores assigned by the MIT program did have some predictive power among the subset of sites it correctly identified.
Comparison with off-target binding sites found by ChIP-seq
We also sought to compare GUIDE-seq with previously described ChIP-seq methods for identifying Cas9 binding sites. Four of the RGNs we evaluated by GUIDE-seq used gRNAs that had been previously characterized in ChIP-seq experiments with catalytically inactive Cas9 (dCas9) 18 . Very little overlap exists between Cas9 off-target cleavage sites identified by GUIDE-seq and dCas9 off-target binding sites identified by ChIP-seq; among the 149 RGN-induced, off-target cleavage sites we identified for the four gRNAs, only 3 were identified in previously published dCas9 ChIP-seq experiments using the same gRNAs (Fig. 4e) . We believe there is little overlap probably because dCas9 off-target binding sites are fundamentally different from Cas9 offtarget cleavage sites; this hypothesis is supported by our data showing that Cas9 off-target cleavage sites for these four gRNAs identified by GUIDE-seq harbor on average far fewer mismatches than the binding sites identified by ChIP-seq ( Fig. 4f) and by the results of previous studies showing that very few dCas9 binding sites show evidence of indels in the presence of active Cas9 (refs. [16] [17] [18] [19] . Although GUIDEseq failed to identify the seven off-target sites previously identified by ChIP-seq and reported to be targets of mutagenesis by Cas9, we think this is because those sites were likely incorrectly identified as bona fide off-target cleavage sites in that earlier study 18 (Supplementary  Results and Supplementary Fig. 6 ). We conclude that very few (if any) dCas9 off-target binding sites discovered by ChIP-seq actually represent bona fide Cas9 off-target cleavage sites.
RGN-independent DSB hotspots identified by GUIDE-seq
Our GUIDE-seq experiments also revealed the existence of 30 unique, RGN-independent, DSB hotspots in the U2OS and HEK293 cells used for our studies ( Supplementary Table 3 ). We uncovered these when analyzing genomic DNA from control experiments with U2OS and HEK293 cells in which we transfected only the dsODN without RGNencoding plasmids. In contrast to RGN-induced DSBs that mapped relatively precisely to specific base-pair positions, RGN-independent, DSB hotspots have dsODN integration patterns that are more broadly dispersed at each locus in which they occur (Supplementary Protocol). These 30 breakpoint hotspots were distributed over many chromosomes and appeared to be present at or near centromeric or telomeric regions (Fig. 5a) . Only two of these hotspots were common to both cell lines whereas the majority appeared to be cell line-specific (25 in U2OS and 7 in HEK293 cells) ( Fig. 5a and Supplementary  Table 3 ).
Analysis of large-scale genomic rearrangements
In the course of analyzing the results of our AMP-based sequencing experiments designed to identify indels at RGN-induced and RGN-independent DSBs, we also discovered that at least some of these breaks can participate in translocations, inversions and large deletions. The AMP method enabled us to observe these large-scale genomic alterations because, for each DSB site examined, it used nested locus-specific primers anchored at only one fixed end rather than a pair of flanking locus-specific primers (Fig. 5b) .
For the five RGNs we examined, AMP sequencing revealed that RGN-induced, on-target and off-target DSBs could participate in a variety of translocations (Fig. 5c) . In at least one case, we identified and NGA sequences 5,23 but also NAA, NGT, NGC and NCG sequences) and a 1-bp 'bulge'-type mismatch 24 at the gRNA/protospacer interface ( Fig. 2a-j) . Protospacer mismatches tended to occur in the 5ʹ end of the target site but could also be found at certain 3ʹ end positions, supporting the concept that there are no simple rules for predicting mismatch effects based on position 4 . Notably, some off-target sites actually had higher sequencing read counts than their matched on-target sites ( Fig. 2a-c,i) , consistent with our previous observations that off-target mutation frequencies can in certain cases be higher than those at the intended on-target site 4 . Many of the previously known off-target sites for four of the RGNs were those with high read counts ( Fig. 2a-d) , suggesting that earlier analyses 4,5 had primarily identified sites that were most efficiently cleaved.
Quantitative analysis of our GUIDE-seq data for nine RGNs enabled us to quantify the potential contributions and impacts of different variables, such as mismatch number, location and type, on off-target site cleavage. We found that the fraction of total genomic sites bearing a certain number of protospacer mismatches that are cleaved by an RGN decreased as the number of mismatches increased (Fig. 3g) .
In addition, GUIDE-seq read counts showed an overall downward trend with increasing numbers of mismatches (Fig. 3h) . In general, protospacer mismatches positioned closer to the 5ʹ end of the target site tended to be associated with smaller decreases in GUIDE-seq read counts than those closer to the 3ʹ end although mismatches positioned 1-4 bp away from the PAM were somewhat better tolerated than those 5-8 bp away (Fig. 3i) . The nature of the mismatch was also associated with an effect on GUIDE-seq read counts. Wobble mismatches occurred frequently in the off-target sites and our analysis suggested they are associated with smaller impacts on GUIDE-seq read counts than other nonwobble mismatches (Fig. 3j) . Consistent with these results, we found that the single factors that explain the greatest degree of variation in off-target cleavage in univariate regression analyses were mismatch number, position and type. By contrast, other factors such as the density of proximal PAM sequences, gene expression level or genomic position (intergenic/intronic/exonic) explained a much smaller proportion of the variance in GUIDE-seq read counts (Fig. 3k) . A combined linear regression model that considered multiple factors including mismatch position, mismatch type, gene expression level and density of proximal PAM sequences yielded results consistent with the univariate analyses ( Supplementary  Fig. 5 ). This analysis also allowed us to independently estimate that, on average and depending on their position, each additional wobble mismatch decreased off-target cleavage rates by approximately twoto threefold, whereas additional nonwobble mismatches decreased cleavage rates by approximately threefold (Supplementary Fig. 5 ).
Comparisons with in silico off-target prediction methods
Having established the efficacy of GUIDE-seq, we next performed direct comparisons of our method with two popular computational programs for predicting off-target mutation sites: the MIT CRISPR Design Tool 25 (http://crispr.mit.edu) and the E-CRISP software 26 (http://www.e-crisp.org/E-CRISP/). Both of these programs identify potential off-target sites based on 'rules' about mismatch number and position. In direct comparisons, we discovered that neither program identified the vast majority of off-target sites found by GUIDE-seq for the nine RGNs (Fig. 4a,b) . Many of these sites were missed because the E-CRISP and MIT programs simply did not consider off-target sites bearing more than three and four mismatches, respectively (Fig. 4c,d) .
Even among the sequences that were considered, these programs still failed to identify the majority of the bona fide off-target sites (Fig. 4c,d) , highlighting their currently limited capability to account for the factors A R T I C L E S npg we also observed large deletions and inversions (Fig. 5c) . We also observed an example of both a large deletion between two RGN-all four possible translocation events resulting from a pair of DSBs (Fig. 5d) . When two DSBs were present on the same chromosome, 
VEGFA site 3 tru-gRNA 0 2,000 4,000 6,000 8,000 Figure 6 GUIDE-seq profiles of RGNs directed by tru-gRNAs. (a) Numbers of previously known and novel off-target cleavage sites identified for RGNs directed to the VEGFA site 1, VEGFA site 3 and EMX1 target sites by matched, full-length gRNAs and truncated gRNAs. Note that the data for the RGNs directed by full-length gRNAs are the same as those presented in Figure 1e and is shown again here for ease of comparison. (b-d) Chromosome ideograms showing on-and off-target sites for RGNs directed to the VEGFA site 1, VEGFA site 3 and EMX1 target sites by matched full-length gRNAs and truncated gRNAs. Note that the ideograms for the RGNs directed by full-length gRNAs are the same as those presented in Figure 1h and Supplementary Figure 3 and are shown again here for ease of comparison. (e) GUIDE-seq-based identification of DSBs induced by RGNs directed by tru-gRNAs. Mapped reads for the on-target sites of the three RGNs directed by tru-gRNAs we assessed by GUIDE-seq. In all cases, the target site sequence is shown with the 17-bp or 18-bp protospacer sequence to the left and the PAM sequence to the right on the x axis. As with RGNs directed by full-length gRNAs, note how the highest peak falls within 3 to 4 bp of the 5ʹ-edge of the NGG PAM sequence, the expected position of an RGN cleavage event. (f-h) Sequences of off-target sites identified by GUIDE-seq for RGNs directed by tru-gRNAs. For each RGN, the intended target sequence is shown in the top line with cleaved sites shown underneath and with mismatches to the on-target site shown and highlighted in color. GUIDE-seq sequencing read counts are shown to the right of each site. The intended on-target site is marked with a black square, previously known off-target sites of RGNs directed by both a full-length gRNA and a tru-gRNA are marked with an open diamond and previously known off-target sites found only with RGNs directed by a tru-gRNA are marked with a gray diamond. Previously known off-target sites were those that were shown to have a mutagenesis frequency of 0.1% or higher in an earlier report 27 . Data are shown for RGNs directed by tru-gRNAs to the VEGFA site 1 (f), VEGFA site 3 (g) and EMX1 target sites (h).
Although our validation experiments show that GUIDE-seq can sensitively detect off-target sites that are mutagenized by RGNs with frequencies as low as ~0.1%, its detection capabilities might be further improved with deeper sequencing. Strategies that use next-generation sequencing to detect indels are limited by the error rate of the platform (typically ~0.1%). By contrast, GUIDE-seq uses sequencing to identify dsODN insertion sites rather than indels and is therefore not limited by error rates but by sequencing depth. For example, we believe that the small number of sites detected in our GUIDE-seq experiments for which we did not find indels in our sequencing validation experiments actually represent sites that likely have indel mutation frequencies below 0.1%. Consistent with this, we note that 23 of these 26 sites had GUIDE-seq read counts below 100. Taken together, these observations suggest that we may be able to increase the sensitivity of GUIDE-seq simply by increasing the number of sequencing reads (and by increasing the number of genomes used as templates for amplification). For example, use of a sequencing platform that yields 1,000-fold more reads might enable detection of sites with mutagenesis frequencies three orders of magnitude lower (i.e., 0.0001%), and we expect further increases to occur with continued improvements in next-generation sequencing technology. Of note, one of the RGNs we assessed did not yield any detectable off-target effects even when we repeated the GUIDE-seq experiment a second time (data not shown). This finding raises the intriguing possibility that some gRNAs may induce very few, or perhaps no, undesired mutations (at least at the current detection limit of these GUIDE-seq experiments).
In direct comparisons, we found that two existing computational programs failed to identify the majority of bona fide off-target sites found by GUIDE-seq. This is not entirely surprising given that parameters used by these programs were based on more restrictive assumptions about the nature of off-target sites that do not account for greater numbers of protospacer mismatches (up to six) and new alternative PAM sequences identified by our GUIDE-seq experiments. It is possible that better predictive programs might be developed in the future but doing so will require experimentally determined, genome-wide, off-target sites for a larger number of RGNs. Until such programs can be developed, identification of off-target sites will be most effectively addressed by experimental methods such as GUIDE-seq.
Our experimental results elaborate a clear distinction between offtarget binding sites of dCas9 and off-target cleavage sites of Cas9. Our results strongly suggest that the binding of off-target sites by dCas9 being captured with ChIP-seq represents a different biological process than cleavage of off-target sites by Cas9 nuclease, consistent with the results of a recent study showing that engagement of the 5ʹ-end of the gRNA with the protospacer is needed for efficient cleavage 19 . Although ChIPseq assays may play a role in characterizing the genome-wide binding of dCas9 fusion proteins, the method is clearly not effective for determining genome-wide, off-target cleavage sites of catalytically active RGNs.
GUIDE-seq has several advantages over other previously described genome-wide methods for identifying DSB sites in cells. The BLESS (breaks labeling, enrichment on streptavidin and next-generation sequencing) oligonucleotide tagging method is performed in situ on fixed, permeabilized cells 28 . In addition to being susceptible to artifacts associated with cell fixation, BLESS will only capture breaks that exist at a single moment. By contrast, GUIDE-seq is performed on living cells and captures DSBs that occur over a more extended period of time (days), thereby making it a more sensitive and comprehensive assay. Capture of integration-deficient lentivirus (IDLV) DNA into regions near DSBs and identification of these loci by LAM-PCR has been used to identify a small number of off-target sites for engineered zinc finger nucleases (ZFNs) 22 and transcription activator-like effector nucleases (TALENs) 29 in human cells. However, IDLV integration events are generally low in number and induced breaks as well as an inversion of that same intervening sequence ( Fig. 5e) . Notably, our results also revealed translocations (and deletions or inversions) between RGN-induced and RGN-independent DSBs (Fig. 5c,f) , suggesting the need to consider the interplay between these two types of breaks when evaluating the off-target effects of RGNs on cellular genomes. Although our data suggested that the frequencies of these large-scale genomic rearrangements are likely to be very low, precise quantification was not possible with the sequencing depth of our existing data set. Increasing the number of sequencing reads should increase the sensitivity of detection and enable better quantification of these important genomic alterations.
GUIDE-seq profiles of RGNs directed by truncated gRNAs
Previous studies from our group have shown that use of gRNAs bearing truncated complementarity regions of 17 or 18 nt can reduce mutation frequencies at known off-target sites of RGNs directed by full-length gRNAs 27 . However, because this analysis was limited to a small number of known off-target sites, the genome-wide specificities of these truncated gRNAs (tru-gRNAs) remained undefined in our earlier experiments. We used GUIDE-seq to obtain genome-wide, DSB profiles of RGNs directed by three tru-gRNAs, each of which was a shorter version of one of the three full-length gRNAs we assayed. In all three cases, the total number of off-target sites identified by GUIDE-seq decreased substantially with use of a tru-gRNA ( Fig. 6a-d) . Mapping of GUIDE-seq reads enabled us to precisely identify the cleavage locations of on-target ( Fig. 6e) and off-target sites (Supplementary Fig. 7) . As expected, included in the list of off-target sites were 10 of the 12 previously known off-target sites for RGNs directed by the three tru-gRNAs ( Figs. 6f-h) . The sequences of the off-target sites we identified primarily had one or two mismatches in the protospacer, but some sites had as many as four ( Fig. 6f-h) . In addition, some sites had alternative PAM sequences of the forms NAG, NGA and NTG ( Fig. 6f-h) . These data provide confirmation on a genome-wide scale that truncation of gRNAs can substantially reduce off-target effects of RGNs and show how GUIDE-seq can be used to assess specificity improvements for the RGN platform.
DISCUSSION
Our studies show that GUIDE-seq provides an unbiased, genome-wide and sensitive method for detecting RGN-induced DSBs. The method is unbiased because it captures DSBs without making assumptions about the nature of the off-target site (e.g., presuming that the off-target site is closely related in sequence to the on-target site). GUIDE-seq identifies off-target sites genome-wide, including within exons, introns and intergenic regions. Although the current lack of a gold-standard method for comprehensively identifying all RGN off-target sites in a cell prevents us from knowing the sensitivity of GUIDE-seq with certainty, we believe that it very likely has a low false-negative rate for the following reasons. First, all RGN-induced DSBs should take up the blunt-ended dsODN by NHEJ, a hypothesis supported by the strong correlations we observed between GUIDE-seq read counts (which measure dsODN uptake) and indel frequencies in the presence of the RGN (which measure rates of DSB formation and of their mutagenic repair) ( Fig. 3b-f ). We note that these correlations include over 130 sites for multiple gRNAs that show a wide range of indel mutagenesis frequencies. Second, using previously identified off-target sites as a benchmark (which is the only way currently to gauge success), GUIDE-seq was able to detect 38 out of 40 of these sites, which show a range of mutagenesis frequencies extending to as low as 0.12%. The method detected all 28 previously known off-target sites for four full-length gRNAs and 10 out of 12 previously known off-target sites for three tru-gRNAs (see Supplementary Discussion for potential explanations of why we did not detect 2 of the 40 sites).
off-target mutations and genomic rearrangements induced by RGNs. GUIDE-seq can most likely be extended for use in any cell in which NHEJ is active and into which the required components can be efficiently introduced; for example, we have already achieved efficient dsODN integration in human K562 and mouse embryonic stem cells (data not shown), and it will be of great interest in future experiments to perform the method in nontransformed primary cells. The strategies outlined here can be used as part of a rigorous preclinical pathway for objectively assessing the potential off-target effects of any RGNs proposed for therapeutic use, thereby substantially improving the prospects for eventual translation of these reagents to the clinic.
METHODS
Methods and any associated references are available in the online version of the paper.
widely dispersed over windows around the actual off-target DSB 22, 29 of 120 bp or more, making it challenging both to precisely map the location of the cleavage event and to infer the sequence of the actual off-target site. In addition, the LAM-PCR process used in previous IDLV capture experiments suffers from potential sequence bias and/or low efficiency of useful sequencing reads. Collectively, these limitations may also explain why certain lower frequency ZFN off-target cleavage sites were not detected in previous studies 30 . By contrast, dsODNs are integrated very efficiently and precisely into DSBs with GUIDE-seq, enabling mapping of breaks with single-nucleotide resolution and simple, straightforward identification of the nuclease off-target cleavage sequences. Furthermore, in contrast to LAM-PCR, our STAT-PCR method allows for efficient, unbiased amplification and sequencing of genomic DNA fragments into which the dsODN has integrated. We note that STAT-PCR may have more general utility beyond its use in GUIDE-seq (e.g., to map the integration sites of viruses on a genomewide scale).
GUIDE-seq also identified breakpoint hotspots that occur in cells even in the absence of RGNs. We believe that these DSBs are not just an artifact of GUIDE-seq because our AMP-based sequencing experiments verified not only capture of dsODNs but also the formation of indels (data not shown) and larger-scale genomic rearrangement involving these sites. Of note, the majority of hotspots we found appeared to be unique to each of the two cell lines examined in our study, but two appeared to be common to both. It will be interesting in future studies to define the parameters that govern why some sites are breakpoint hotspots in one cell type but not another. Also, because our results show that these breakpoints can participate in translocations, the existence of cell type-specific hotspots might help to explain why certain genomic rearrangements occur only in specific cell types but not in others. To our knowledge, GUIDE-seq is the first method to be described that can identify breakpoint hotspots in living human cells without the need to add drugs that inhibit DNA replication (e.g., aphidicolin) 28 . Therefore, we expect that it will provide a useful general tool for identifying and studying these breaks.
Our work establishes a qualitative approach for identifying translocations induced by RGNs. AMP-based targeted sequencing of RGNinduced and RGN-independent DSBs discovered by GUIDE-seq can find large-scale genomic rearrangements (translocations, deletions and inversions) involving both classes of sites, highlighting the importance of examining all of these loci. In addition, presumably not all RGNinduced or RGN-independent DSBs will participate in large-scale alterations, and understanding why some sites do and other sites do not contribute to these rearrangements will be an important area for further research.
GUIDE-seq will also provide a way to evaluate alterations to the RGN platform on a genome-wide scale. In this report, we used GUIDE-seq to show that the use of truncated gRNAs can reduce genome-wide, offtarget effects. We envision that GUIDE-seq might also be used to assess the specificities of alternative Cas9 nucleases from other bacteria or archaea 31 . GUIDE-seq might also be adapted to assess the genome-wide specificities of nucleases such as dimeric ZFNs, TALENs and CRISPR RNA-guided FokI nucleases (RFNs) 32,33 that generate 5ʹ overhangs or paired Cas9 nickases 34, 35 that generate 5ʹ or 3ʹ overhangs. In preliminary experiments, we have already shown that blunt dsODN can be captured into ZFN-, TALEN-and RFN-induced breaks (data not shown); however, extending GUIDE-seq to detect these other types of DSBs will undoubtedly require additional modification of the dsODN to optimize its efficient capture into such breaks.
We expect that our overall approach using GUIDE-seq and AMPbased sequencing will prove to be very useful for the evaluation of
